ORIGINAL RESEARCH
Published on 14 May 2025
Olverembatinib (HQP1351)-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in blast phase: results from a real-world study
doi 10.3389/fimmu.2025.1546371
- 784 views